What's Happening With HIMS Stock?
HIMS has risen 40% pre-market following reports of a settlement and collaboration with Novo Nordisk to market its branded weight-loss drug on the Hims platform.
5 Things to Know Before the Stock Market Opens
Stock futures are sharply lower Monday as investors grow increasingly concerned about the impact of the war in the Middle East on the global economy; Oil prices jumped to their highest level in nearly four years as the war hampers the commodity's supply chain; Hims & Hers Health stock is surging on reports of a deal with Novo Nordisk to sell its weight loss products on the platform; Kalshi and Polymarket are reportedly in talks for new funding rounds that would value the prediction markets at $20 billion each; and HP Enterprise is set to kick off a busy week of earnings. Here's what you need to know today.
Hims shares jump after report of Novo Nordisk partnership that may end legal feud
Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans to sell its weight-loss drugs on the telehealth firm's platform, signaling a potential end to the dispute between the two companies.
Hims & Hers Shares Double on Report of Wegovy Tie-Up
Stock skyrocketed premarket following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform.
Why did HIMS stock rally 40% within hours?
Hims & Hers (NYSE: HIMS) Health stock experienced a dramatic surge in after-hours trading on Friday, transforming what had been a subdued regular session into one of the most explosive moves of the day.
Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Hims and Hers Expands Its Technology Driven Consumer Health Platform
HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVO
Forward-looking guidance initially plagued Hims & Hers (HIMS) shares, says Christine Short, though she believes leadership did a good job at "refocusing" goals. She points to the company's businesses beyond GLP-1s showing signs of promise.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.
Hims & Hers Health: Don't Get Lost In The Weeds
Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensus, and expects strong subscriber growth in weight loss offerings despite temporary GLP-1 headwinds. The Eucalyptus acquisition is set to add at least $200 million to 2026 revenues, positioning HIMS for a $3.25–$4 billion annualized run rate entering 2027.
